Cetuximab Activity in Dysplastic Lesions of the Upper Aerodigestive Tract

BACKGROUND: High risk head and neck mucosal premalignancy has a malignant conversion rate of up to 40%, despite adequate surgical therapy. Epidermal Growth Factor Receptor (EGFR) blocking agents, including cetuximab, have shown activity in head and neck squamous cell carcinoma (HNSCC) and have poten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Khan, Zubair, Epstein, Joel B, Marur, Shanthi, Gillespie, M Boyd, Feldman, Lawrence, Tsai, Hua-Ling, Zhang, Zhe, Wang, Hao, Sciubba, James, Ferris, Robert, Grandis, Jennifer R, Gibson, Michael, Koch, Wayne, Tufano, Ralph, Westra, William, Tsottles, Nancy, Ozawa, Hiroyuki, Chung, Christine, Califano, Joseph A
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751887/
https://ncbi.nlm.nih.gov/pubmed/26686755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados